Follow-On Biologics: Defeat For Waxman, Win For Health Reform
This article was originally published in The Pink Sheet Daily
Executive Summary
Lopsided committee vote suggests that lengthy exclusivity is here to stay, which means that big pharma can get more comfortably behind the broader reform effort.